Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine

Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant

(2012) Murdo Ferguson et al.   JOURNAL OF INFECTIOUS DISEASES

Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older

(2012) Hideyuki Ikematsu et al.   Human Vaccines & Immunotherapeutics

Safety and persistence of immunological response 6 months after intramuscular vaccination with an AS03-adjuvanted H1N1 2009 influenza vaccine

(2012) Akihiko Saitoh et al.   Human Vaccines & Immunotherapeutics

Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults

(2012) Hideyuki Ikematsu et al.   Human Vaccines & Immunotherapeutics

Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials

(2011) François Roman et al.   Clinical and Vaccine Immunology

Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan

(2011) Hideyuki Ikematsu et al.   Human vaccines & immunotherapeutics

AS03A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age

(2010) François Roman et al.   CLINICAL INFECTIOUS DISEASES

Protective Efficacy of Seasonal Influenza Vaccination against Seasonal and Pandemic Influenza Virus Infection during 2009 in Hong Kong

(2010) Benjamin J. Cowling et al.   CLINICAL INFECTIOUS DISEASES

H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses

(2010) Philippe Moris et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial

(2010) Karl G Nicholson et al.   LANCET INFECTIOUS DISEASES

An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers

(2010) Abdullah S. Madhun et al.   VACCINE

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months

(2010) Alfonso Carmona et al.   VACCINE

Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial

(2009) Zoltan Vajo et al.   LANCET

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial

(2009) François Roman et al.   VACCINE

Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study

(2009) Isabel Leroux-Roels et al.   VACCINE

Age-related decline in immunity: implications for vaccine responsiveness

(2008) Rajesh Kumar et al.   Expert Review of Vaccines

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children

(2008) Terry Nolan et al.   VACCINE